<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70426">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01815541</url>
  </required_header>
  <id_info>
    <org_study_id>PI2012_843_0008</org_study_id>
    <secondary_id>2012-003690-25</secondary_id>
    <nct_id>NCT01815541</nct_id>
  </id_info>
  <brief_title>Administration of Subcutaneous Teicoplanin in the Treatment of Osteoarticular Infections: Tolerance Study</brief_title>
  <official_title>Administration of Subcutaneous Teicoplanin in the Treatment of Osteoarticular Infections: Tolerance Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a biomedical research, prospective, mono centric, tolerance study Of the
      administration of subcutaneous teicoplanin in the treatment of osteoarticular infections.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>measure of tolerance</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The frequencies of adverse reactions at the injection site SC will be measured to assess the local tolerance of teicoplanin by SC.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Osteoarticular Infection</condition>
  <arm_group>
    <arm_group_label>teicoplanin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>this group receive the teicoplanin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teicoplanin</intervention_name>
    <arm_group_label>teicoplanin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient over 18 years

          -  Inpatient orthopedic surgery

          -  Achieved a bone and joint infection documented gram + (staphylococci golden
             coagulase-negative staphylococci, enterococci, streptococci)

          -  Bacteria resistant to lincosamides, quinolones and rifampicin

          -  Bacteria susceptible to teicoplanin (MIC ≤ 4 mg / L)

          -  Balanced patient teicoplanin administered intravenously (2 successive doses between
             30 and 40 mg / mL)

        Exclusion Criteria:

          -  Patient not affiliated to the social security

          -  Pregnant and lactating women

          -  Known hypersensitivity to teicoplanin (rash, ...)

          -  Patients with a central catheter or an implantable chamber

          -  Patient hemodialysis

          -  Patient has another participant biomedical research on a drug to prevent drug
             interactions

          -  Patient minor

          -  Patient major protected (protection of the court, wardship, trusteeship)

          -  Patient admitted for emergency or incapable of consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Youssef El SAMAD, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Youssef El SAMAD, PH</last_name>
    <phone>00333 22 66 88 13</phone>
    <email>elsamad.youssef@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <state>Picardie</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Youssef EL SAMAD, PH</last_name>
      <phone>333 22 66 88 13</phone>
      <email>elsamad.youssef@chu-amiens.fr</email>
    </contact>
    <contact_backup>
      <last_name>Mohamed AIT AMER MEZIANE, CRA</last_name>
      <phone>03.22.66.80.60</phone>
      <email>aitamermeziane.mohamed@chu-amiens.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 19, 2013</lastchanged_date>
  <firstreceived_date>March 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>subcutaneous teicoplanin</keyword>
  <keyword>osteoarticular</keyword>
  <keyword>infections</keyword>
  <keyword>tolerance</keyword>
  <keyword>teicoplanin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Teicoplanin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
